Global burden of acute lower respiratory infection associated with human parainfluenza virus in children younger than 5 years for 2018: a systematic review and meta-analysis

Abstract

Background Human parainfluenza virus (hPIV) is a common virus in childhood acute lower respiratory infections (ALRI). However, no estimates have been made to quantify the global burden of hPIV in childhood ALRI. We aimed to estimate the global and regional hPIV-associated and hPIV-attributable ALRI incidence, hospital admissions, and mortality for children younger than 5 years and stratified by 0-5 months, 6-11 months, and 12-59 months of age. MethodsWe did a systematic review of hPIV-associated ALRI burden studies published between Jan 1, 1995, and Dec 31, 2020, found in MEDLINE, Embase, Global Health, Cumulative Index to Nursing and Allied Health Literature, Web of Science, Global Health Library, three Chinese databases, and Google search, and also identified a further 41 high-quality unpublished studies through an international research network. We included studies reporting community incidence of ALRI with laboratory-confirmed hPIV; hospital admission rates of ALRI or ALRI with hypoxaemia in children with laboratory-confirmed hPIV; proportions of patients with ALRI admitted to hospital with laboratory-confirmed hPIV; or in-hospital case-fatality ratios (hCFRs) of ALRI with laboratory-confirmed hPIV. We used a modified Newcastle-Ottawa Scale to assess risk of bias. We analysed incidence, hospital admission rates, and hCFRs of hPIV-associated ALRI using a generalised linear mixed model. Adjustment was made to account for the non-detection of hPIV-4. We estimated hPIV-associated ALRI cases, hospital admissions, and in-hospital deaths using adjusted incidence, hospital admission rates, and hCFRs. We estimated the overall hPIV-associated ALRI mortality (both in-hospital and out-hospital mortality) on the basis of the number of in-hospital deaths and care-seeking for child pneumonia. We estimated hPIV-attributable ALRI burden by accounting for attributable fractions for hPIV in laboratory-confirmed hPIV cases and deaths. Sensitivity analyses were done to validate the estimates of overall hPIVassociated ALRI mortality and hPIV-attributable ALRI mortality. The systematic review protocol was registered on PROSPERO (CRD42019148570).Findings 203 studies were identified, including 162 hPIV-associated ALRI burden studies and a further 41 high-quality unpublished studies. Globally in 2018, an estimated 18•8 million (uncertainty range 12•8-28•9) ALRI cases, 725 000 (433 000-1 260 000) ALRI hospital admissions, and 34 400 (16 400-73 800) ALRI deaths were attributable to hPIVs among children younger than 5 years. The age-stratified and region-stratified analyses suggested that about 61% (35% for infants aged 0-5 months and 26% for 6-11 months) of the hospital admissions and 66% (42% for infants aged 0-5 months and 24% for 6-11 months) of the in-hospital deaths were in infants, and 70% of the inhospital deaths were in low-income and lower-middle-income countries. Between 73% and 100% (varying by outcome) of the data had a low risk in study design; the proportion was 46-65% for the adjustment for health-care use, 59-77% for pat...

Recent increase in the detection of human parainfluenza virus during the coronavirus disease-2019 pandemic in the Republic of Korea

“…The implementation of high-intensity social These changes resulted in an unprecedented increase in the detection rate of hPIV, especially in the young age groups, in September 2021 in the Republic of Korea. Among the enveloped viruses, hPIV is the most common pathogen causing common cold in infants [18,19]. Most children over 5 years of age possess antibodies against hPIV3 [20,21]; however, infants are vulnerable to hPIV3 infection [22,23].…”

Vimentin inhibits α-tubulin acetylation via enhancing α-TAT1 degradation to suppress the replication of human parainfluenza virus type 3

“…Infectious respiratory viral diseases pose a great threat to human health globally. The human parainfluenza virus type 3 (HPIV3) is the most pathogenic HPIV, causing lower respiratory tract infections in children, infants, and people with weakened immunity [1,2]. HPIV3 belongs to the Paramyxovirus family, and its viral particles have a negative-strand RNA genome and six structural proteins, including the nucleocapsid protein (N), the phosphoprotein (P), the matrix protein (M), the fusion protein (F), the hemagglutinin and neuraminidase (HN), and the RNA-dependent RNA polymerase (L) [3].…”

Modeling Infection and Tropism of Human Parainfluenza Virus Type 3 in Ferrets

“…Respiratory viruses affect millions of children globally each year, are an important cause of mortality in the elderly, and are a growing problem in the immunocompromised ( 1 – 4 ). However, for most of these viruses no specific vaccines or treatments are available.…”

“…HPIV-3 is responsible for more hospitalizations than HPIV-1 and -2 combined ( 8 , 28 , 29 ). HPIV-3 transmission occurs via the respiratory route, and inpatient nosocomial outbreaks are common, causing considerable morbidity and mortality in high-risk groups ( 2 , 30 – 35 ). Academic hospitals have seen a shift in the profile of HPIV-3 patients, resulting in an increased number of immunocompromised patients with severe comorbidities.…”